<DOC>
	<DOCNO>NCT01785420</DOCNO>
	<brief_summary>Background Information Rationale : Trastuzumab humanize monoclonal antibody act extracellularly erbB-2 receptor.Trastuzumab recombinant humanize IgG1 monoclonal antibody human epidermal growth factor receptor 2 ( HER2/erbB-2 ) , show vitro assay animal , inhibit proliferation human tumour cell overexpress erbB-2 . Additionally , trastuzumab potent mediator antibody-dependent cell-mediated cytotoxicity ( ADCC ) . In vitro , trastuzumab-mediated ADCC show preferentially exert erbB-2 overexpressing cancer cell compare cancer cell overexpress erbB-2 . Trastuzumab emerge widely accept standard care erbB-2-positive disease . ( Metastatic/ adjuvant/neoadjuvant . Our current hypothesis suggest cell disseminated time surgery encounter inhospitable environment anti-HER nature . Therefore combine mention stream think , would like assess effect short pre-operative course Trastuzumab breast cancer relapse . The study propose HER2 positive patient operable breast cancer . Objectives : Primary : The primary objective study see effect short duration peri-operative Trastuzumab disease-free survival comparison patient Secondary : The safety pre-operative therapy include early post operative morbidity 1 . Overall survival ( OS ) patient pathologically node positive patient . 2 . The level circulate tumor cell ( CTCs ) peripheral blood assess start pre-operative therapy time point control arm , level CTCs 10 minute prior start surgery , surgery 10 day surgery 40 consecutive consenting patient ( 20 arm ) . The level circulate chromatin also estimate time point CTC 40 patient . 3 . Evaluation paraffin block pTEN loss6-8 p95ErbB2 truncate form HER2 100 consecutive consenting patient ( 50 arm ) .9-11 Study Design : This phase 3 , randomize Double blind parallel group study Trastuzumab pre operative set operable breast cancer patient . Approximately 1000 patient Women HER2neu positive , T1/T2/T3 N0/N1 . clinical T4 and/or N2 disease consider operable treat surgeon histopathological diagnosis core biopsy , include study . Patients T4 N2 ( locally advance large operable neo-adjuvant chemotherapy ) include . All node positive patient receive single injection Depot Inj . Progesterone 500 mg deep IM 4 -14 day prior surgery Patients stratify , randomization Tumor size , menopausal status , affordability Trastuzumab centre study . These patient randomize 1:1 receive follow Intervention arm : .A single dose Trastuzumab ( Herceptin , Hoffman La Roche ) 8 mg/Kg 90 minute intravenous infusion 250 ml normal saline , window period 10-15 4 14 day ( day inclusive ) prior plan date surgery . Control arm : A 90 minute intravenous infusion saline placebo All patient thereafter receive standard post-operative adjuvant therapy per local institutional practice include hormonal therapy , chemotherapy radiation therapy .</brief_summary>
	<brief_title>Pre Operative Trastuzumab Operable Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>. 1 . Female subject age 18 year old . 2 . Histologically and/or cytologically confirm diagnosis breast cancer . Clinical stage breast cancer : HER2 positive , T1 T2 T3 , N0 N1 , resectable T4 , resectable N2 , ( M0 ) 3 . Documentation erbB2 gene amplification FISH ( define ratio &gt; 2.2 ) chromogenic situ hybridization ( CISH , define manufacturer 's kit instruction ) documentation erbB2overexpression IHC ( define IHC3+ , IHC2+ FISH CISH confirmation ) base local laboratory . 4 . LVEF within institutional range normal measure MUGA ECHO . 5 . Screening laboratory value within follow parameter : 1 . Absolute neutrophil count ( ANC ) ≥1.5 x 109 /L ( 1500/mm3 ) 2 . Platelet count ≥100 x 109/L ( 100,000/mm3 ) 3 . Hemoglobin ≥9.0 g/dL ( 90 g/L ) 4 . Serum creatinine ≤1.5 x upper limit normal ( ULN ) 5 . Total bilirubin ≤1.5 x ULN ( &lt; 3 ULN Gilbert 's disease ) 6Aspartate aminotransferase ( AST ) and/or alanine aminotransferase ( ALT ) 2.5 x ULN 1 . Bilateral breast cancer 2 . Active uncontrolled cardiac disease , include cardiomyopathy , CHF ( New York Heart Association [ NYHA ] functional classification ≥3 ) , unstable angina , myocardial infarction ( within 12 month study entry ) . 3 . Inadequately control hypertension ( ie , systolic blood pressure [ BP ] &gt; 180 mm Hg diastolic BP &gt; 100 mm Hg ) . 4 . Family history congenital long short QT syndrome , Brugada syndrome QT/QTc interval &gt; 0.45 second know history QT/QTc prolongation torsade de pointe ( TdP ) . 5 . Significant chronic gastrointestinal disorder diarrhea major symptom ( eg , Crohn 's disease , malabsorption , grade ≥2 diarrhea etiology baseline ) . 6 . Women pregnant , breastfeeding .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Pre-operative Trastuzumab Protocol</keyword>
</DOC>